Azienda Ospedaliera Istituti Ospitalieri di Cremona
Welcome,         Profile    Billing    Logout  
 4 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Generali, Daniele
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Recruiting
N/A
150
Europe
University of Milano Bicocca
Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
01/24
01/24
PALMARES-2, NCT06805812: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian Study

Recruiting
N/A
3500
Europe
Palbociclib, Ribociclib, Abemaciclib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, European Institute of Oncology, Italy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, OSPEDALE ASST CREMONA, IOV Oncologico Veneto Padova, ASST Fatebenefratelli Sacco, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, A.O.U. Federico II, Napoli, San Raffaele University Hospital, Italy, Centro di Riferimento Oncologico - Aviano, Azienda Socio-Sanitaria Territoriale Lariana, Azienda ULSS 3 Serenissima, Ospedale di Mirano, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliero-Universitaria Careggi, Humanitas, Istituto Clinico Catanese, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Fondazione Policlinico Universitario Campus Bio-Medico, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors
12/30
12/40
BREVITY, NCT03524430: RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

Recruiting
N/A
801
Europe, Canada, US
Core needle biopsy
Rna Diagnostics Inc.
Breast Neoplasm Female
07/25
03/30
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Generali, Daniele
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
HERMIONE-13, NCT05173103: Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer

Recruiting
N/A
150
Europe
University of Milano Bicocca
Advanced Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
01/24
01/24
PALMARES-2, NCT06805812: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian Study

Recruiting
N/A
3500
Europe
Palbociclib, Ribociclib, Abemaciclib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, European Institute of Oncology, Italy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, OSPEDALE ASST CREMONA, IOV Oncologico Veneto Padova, ASST Fatebenefratelli Sacco, IRCCS Fondazione Salvatore Maugeri, Pavia, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, A.O.U. Federico II, Napoli, San Raffaele University Hospital, Italy, Centro di Riferimento Oncologico - Aviano, Azienda Socio-Sanitaria Territoriale Lariana, Azienda ULSS 3 Serenissima, Ospedale di Mirano, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Fondazione IRCCS Policlinico San Matteo di Pavia, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Ospedaliero-Universitaria Careggi, Humanitas, Istituto Clinico Catanese, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Fondazione Policlinico Universitario Campus Bio-Medico, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors
12/30
12/40
BREVITY, NCT03524430: RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

Recruiting
N/A
801
Europe, Canada, US
Core needle biopsy
Rna Diagnostics Inc.
Breast Neoplasm Female
07/25
03/30
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26

Download Options